Registration - In-house Corporation

Baxter Corporation / Stephen Thompson, President & General Manager

Registration Information

In-house Corporation name: Baxter Corporation
Responsible Officer Name: Stephen Thompson, President & General Manager
Responsible Officer Change History
Initial registration start date: 2007-01-31
Registration status: Inactive
Registration Number: 930614-14650

Associated Communications

Total Number of Communication Reports: 17

Monthly communication reports in the last 6 months: 0

Version 4 of 22 (2010-03-09 to 2010-09-20)

Registration versions:

Version 4 of 22 (2010-03-09 to 2010-09-20)

Lobbying Information

Subject Matters

Environment
Government Procurement
Health
Industry
Intellectual Property
International Relations
International Trade
Science and Technology
Taxation and Finance

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Canada's Pandemic Influenza Supply Strategy with respect to revising the national strategy for 2011 and response to the 2010 RFP in context of Baxter's pandemic influenza vaccine

Legislative Proposal, Bill or Resolution

Bill C-51 (An Act to Amend the Food and Drugs Act) - with respect to provisions that would impact approvals and prodcut life-cycle management for medical devices and biopharmacetucials, subsequent entry biologics regulations and the disclosure of confidential business information
Federal Budget & Budget measures act with respect to health care funding and focus on science & technology strategy

Policies or Program

Federal Chemicals Management Plan - with repsect to specific batch chemical reviews that may include a chemical used in our manufacturing operations in Canada
Good Manufacturing Practices (GMP) 2007 Proposed Guidelines - with respect to sterilization processes and labeling changes
Health Canada's Proposal to Parliament for User Fees and Service Standards for Human Drugs and Medical Devices Programs - with respect to user fees/cost recovery for new drug and medical device evaluations
Patented Medicines Prices Review Board (PMPRB) policies and guidelines - with respect to the implementation of the revised excessive price guidelines
Science & Technology strategy with respect to the impact on commcercialization of medical technology in Canada
Subsequent Entry Biologics (SEB's) policy guidelines - with repsect to exemptions for blood/plasma-derived products, recombinant technology and/or cell-gene-based technologies

Regulation

Regulations Amending the Food and Drug regulations (1319 - New Drugs for Extraordinary Use (EUND) - Canada Gazette Part 1 (April 3, 2010)

Communication Techniques

Written communication
Oral communication

Government Institutions

Canada Border Services Agency (CBSA)
Environment Canada
Finance Canada (FIN)
Foreign Affairs and International Trade Canada (DFAITC)
Health Canada (HC)
House of Commons
Industry Canada
National Defence (DND)
Office of the Procurement Ombudsman (OPO)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Public Health Agency of Canada (PHAC)
Public Safety Canada (PS)
Public Works and Government Services Canada
Senate of Canada

In-house Corporation Details

Description of activities

Baxter Corporation is the Canadian subsidiary of Baxter International, a global health care company. Baxter's BioScience, Medication Delivery and Renal products and services are used to treat Canadians with such medical conditions as cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease and trauma.

Responsible officer name and position during the period of this registration

Barbara Leavitt, President

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
4 Robert Speck Parkway, Ste. 700
Mississauga, ON L4Z 3Y4
Canada

Telephone number: 905-281-6828
Fax number: 905-281-6570

Parent Company Information

Baxter International
- One Baxter Parkway
  Deerfield, IL 60015-4625
  United States of America

Subsidiary Beneficiary Information

Baxter Corporation does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Lisa Armour, Director, Regulatory Affairs | No public offices held
Pam Bobbette, VP, Quality Assurance | No public offices held
Barb Leavitt, President | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Saurabh Popat, Director Government Affairs & Public Policy | No public offices held

Baxter Corporation

The following names have been used on or after July 2, 2008

Name	From	To
Baxter Corporation	2010-03-09	2020-11-17

The following names have been used before July 2, 2008

Baxter Corporation

Baxter Corporation

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Stephen Thompson	2017-02-06	2020-11-17
Mike Oliver	2011-10-03	2015-11-02
Barbara Leavitt	2007-01-31	2011-10-03

Date Modified:: 2025-04-30

Search and menus

Language selection

Registration - In-house Corporation

Baxter Corporation / Stephen Thompson, President & General Manager

Registration Information

Associated Communications

Version 4 of 22 (2010-03-09 to 2010-09-20)

Version 4 of 22 (2010-03-09 to 2010-09-20)

Subject Matters

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Legislative Proposal, Bill or Resolution

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties